The FDA topped off last week with two approvals under its popular Real-Time Oncology Review (RTOR) program, granting new indications to AstraZeneca PLC/Daiichi Sankyo Co., Ltd.’s Enhertu in HER2-low breast cancer and Bayer AG/Orion Corporation’s Nubeqa in hormone-sensitive prostate cancer.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?